Latest news about Mercury Laboratories
Mercury Laboratories
805.00
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M+7.33%
6M-3.65%
1Y-1.99%
5Y+9.28%
More news about Mercury Laboratories
12Nov 25
Mercury Laboratories Postpones New Injectable Plant Commissioning to December 2026
Mercury Laboratories has postponed the commissioning of its new Small Volume Parenteral (SVPs) manufacturing plant from November 2025 to December 2026, citing revisions in Schedule M guidelines by the Ministry of Health and Family Welfare. The facility, located at Jarod, has a planned annual capacity of 75 million units with an investment of INR 30.00 crores. The company states the delay will not materially impact overall business operations. Recent financial results show significant year-over-year growth in both quarterly and half-yearly net profits.
12Nov 25
Mercury Laboratories Reports 70% Surge in Q2 Net Profit, Revenue Up 4.8%
Mercury Laboratories Limited announced Q2 FY2026 results with revenue at ₹1,900.86 lakhs, up 4.8% quarter-on-quarter. Net profit surged 69.8% to ₹164.33 lakhs. H1 FY2026 revenue reached ₹3,714.40 lakhs with ₹261.09 lakhs net profit. EPS for Q2 increased to ₹13.69. The company deferred its new SVP plant commissioning to December 2026 due to revised regulatory guidelines.
04Nov 25
Mercury Laboratories Appoints Seema Salvi as Head of Injectable Production Department
Mercury Laboratories Limited has appointed Ms. Seema Salvi as the Head of the Injectable Production Department, effective November 04, 2025. Ms. Salvi, 49, brings over 26 years of experience in injection production to her new role. She holds a Bachelor's degree in Pharmacy and has previously worked with Harson Laboratories India Pvt. Ltd. and Crescent Labs Pvt Ltd. This full-time appointment to the senior management team aims to strengthen the company's production capabilities in the injectable drugs segment.
13Aug 25
Mercury Laboratories Reports 183% Jump in Net Profit with Strong Revenue Growth
Mercury Laboratories Limited reported strong financial results for the recent quarter. Total revenue increased by 8.9% to ₹18.32 crore, while net profit after tax surged by 183.3% to ₹96.76 lakh. The EBITDA margin expanded to 13.9% from 10.5%. Revenue from operations grew by 8.7% to ₹18.14 crore. The company's performance was attributed to higher operating leverage, improved cost management, and a favorable product mix. Despite increases in material costs and employee expenses, effective cost control measures led to a 9.4% decrease in other expenses to ₹4.29 crore.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,774.00
(-0.81%)
6,648.00
(+1.09%)
4,388.10
(+0.45%)
1,376.50
(+0.09%)
1,085.90
(+0.86%)
1,266.80
(+0.28%)
2,261.00
(-0.01%)
2,347.60
(-0.92%)
1,452.40
(+0.83%)
1,427.10
(+2.35%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
